

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this report, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this report.



廣州白雲山醫葯集團股份有限公司

GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS CO., LTD.

(a joint stock company with limited liability established in the People's Republic of China)

(H Share Stock Code: 0874)

2022 THIRD QUARTERLY REPORT

IMPORTANT NOTICE

The board of directors (the “**Board**”), the supervisory committee of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (the “**Company**”) and its directors, supervisors and senior management collectively and individually accept full responsibility for the truthfulness, accuracy and completeness of the information contained in this quarterly report and confirm that there are no false information, misleading statements or material omissions in this quarterly report.

Mr. Li Chuyuan (chairperson of the Board), Ms. Liu Fei (deputy financial officer) and Ms. Wu Chuling (deputy director of the Financial Department) declared that they warranted that the financial reports contained in this quarterly report were true, accurate and complete.

The third quarterly financial reports were audited.

Yes No

This quarterly report is prepared in both English and Chinese. In the event that different interpretation occurs, the Chinese version shall prevail.

1. PRINCIPAL FINANCIAL DATA

1.1 Principal accounting data and financial indicators

Items	The Reporting Period (1 July 2022 – 30 September 2022) (Unaudited)	Increase/(Decrease) during the Reporting Period as compared with the corresponding period of 2021 (%)	From the beginning of 2022 to the end of the Reporting Period (1 January 2022 – 30 September 2022) (Unaudited)	Increase/(Decrease) from the beginning of 2022 to the end of the Reporting Period as compared with the corresponding period of 2021 (%)
Income from operations (RMB'000)	17,585,465	1.00	54,805,915	2.37
Net profit attributable to the shareholders of the Company (RMB'000)	884,371	9.27	3,474,367	4.91
Net profit attributable to the shareholders of the Company after deducting non-recurring items (RMB'000)	833,660	5.23	3,134,035	(4.68)
Net cash flow from operating activities (RMB'000)	Not applicable	Not applicable	3,299,470	(42.97)
Basic earnings per share (RMB/Share)	0.544	9.27	2.137	4.91
Diluted earnings per share (RMB/Share)	0.544	9.27	2.137	4.91
Ratio of weighted average return on net assets (%)	2.85	A decrease of 0.02 percentage point	11.42	A decrease of 0.62 percentage point
			As at the end of the Reporting Period (Unaudited)	Increase/(Decrease) as at the end of the Reporting Period as compared with 31 December 2021 (%)
			31 December 2021 (Audited)	
Total assets (RMB'000)		69,552,608	66,117,790	5.19
Total equity attributable to the shareholders of the Company (RMB'000)		31,428,817	29,062,184	8.14

- Notes: (1) “Reporting Period” refers to the three-month period from the beginning of this quarter to the end of this quarter and the same meaning applies to the contents below.
- (2) The above financial data and indicators are computed based on the figures on consolidated basis.

1.2 Non-recurring items and amount

Items	Amount of 1 July 2022 – 30 September 2022 (RMB'000)	Amount of 1 January 2022 – 30 September 2022 (RMB'000)	Notes
Gain/(Loss) on disposal of non-current assets	(754)	(1,625)	
Government subsidies included in the profit or loss for the current period except for the government subsidies that are closely related to enterprise's normal business and is enjoyed by the Company continuously in quota or by the quantity of unified national standards in accordance with the national policy	39,187	358,972	This represents the amount of government grants received by the Company and its subsidiaries, which were transferred to non-operating income and other gains in the period.
Except for effective hedging business related to normal business of the Company, profit or loss from change of fair value from trading financial assets, derivative financial assets, trading financial liabilities and derivative financial liabilities, and investment income from disposal of trading financial assets, derivative financial assets, trading financial liabilities, derivative financial liabilities and other debt instruments	32,030	51,088	
Reverse of provision for impairment of receivables under individual impairment test	143	18,155	
Other non-operating income and expenses excluding the above items	(3,307)	(2,181)	
Less: Income tax effect	13,292	74,916	
Effect on minority interest (after tax)	3,296	9,161	
Total	<u>50,711</u>	<u>340,332</u>	

Explanation of non-recurring profit or loss items listed in the “Explanatory Announcement No. 1 on Information Disclosure by Companies Offering Their Securities to the Public – Extraordinary Profit and Loss Items” (《公開發行證券的公司信息披露解釋性公告第1號—非經常性損益》) being defined as recurring profit or loss items

Applicable Not applicable

1.3 Changes in major accounting data and financial indicators of the Company and the reasons for changes

✓ Applicable □ Not applicable

Items	Fluctuation (%)	Reasons for fluctuation
Net cash flow from operating activities	(42.97)	From January to September in 2022, net cash flow from operating activities decreased year-on-year due to: (1) as the 2022 Spring Festival was earlier than the 2021 Spring Festival, the receipt of payments for the sale of goods by Guangzhou WLJ Great Health Industry Co., Ltd., a wholly-owned subsidiary of the Company, during the 2022 Spring Festival partly took place in the end of 2021, resulting in a year-on-year decrease in net cash flow from operating activities; (2) the cash receipt from the sale of goods and the rendering of service by the Company's subsidiaries decrease year-on-year.

2. INFORMATION OF SHAREHOLDERS

The total number of shareholders holding ordinary shares, the number of shareholders holding preferred shares whose voting rights are restored and the shareholdings of the top ten shareholders of the Company

The total number of shareholders holding ordinary shares as at the end of the Reporting Period		98,511	The total number of shareholders holding preferred shares whose voting rights are restored as at the end of the Reporting Period (if any)		Not applicable	
The top ten shareholders of the Company						
Shareholders	Nature of shareholders	Number of shares held (share)	Approximate percentage of the total issued share capital (%)	Number of shares subject to selling restrictions (share)	Number of shares pledged, marked or frozen Shares status Number of shares (share)	
Guangzhou Pharmaceutical Holdings Limited	State-owned legal person	732,305,103	45.04	0	Nil	0
HKSCC Nominees Limited	Others	219,767,290	13.52	0	Nil	0
Guangzhou China Life Urban Development Industry Investment Enterprise (Limited Partnership)	Others	73,313,783	4.51	0	Nil	0
Guangzhou Industrial Investment and Capital Operation Holding Group Ltd.	State-owned legal person	55,548,800	3.42	0	Nil	0
China Securities Finance Corporation Limited	Others	47,277,962	2.91	0	Nil	0
Hong Kong Securities Clearing Company Limited	Others	44,044,499	2.71	0	Nil	0
China AMC – Agricultural Bank – Huaxia China Securities Financial Asset Management Plan	Others	8,795,136	0.54	0	Nil	0
Zhongou AMC – Agricultural Bank – Zhongou China Securities Financial Asset Management Plan	Others	8,680,636	0.53	0	Nil	0
Boshi AMC – Agricultural Bank – Boshi China Securities Financial Asset Management Plan	Others	8,662,836	0.53	0	Nil	0
Dacheng AMC – Agricultural Bank – Dacheng China Securities Financial Asset Management Plan	Others	8,657,836	0.53	0	Nil	0

The top ten shareholders of the Company not subject to selling restrictions

Shareholders	Number of shares without selling restrictions (share)	Class and number of shares Class of shares	Number of shares (share)
Guangzhou Pharmaceutical Holdings Limited	732,305,103	Domestic shares denominated in RMB	732,305,103
HKSCC Nominees Limited	219,767,290	H shares	219,767,290
Guangzhou China Life Urban Development Industry Investment Enterprise (Limited Partnership)	73,313,783	Domestic shares denominated in RMB	73,313,783
Guangzhou Industrial Investment and Capital Operation Holding Group Ltd.	55,548,800	Domestic shares denominated in RMB	55,548,800
China Securities Finance Corporation Limited	47,277,962	Domestic shares denominated in RMB	47,277,962
Hong Kong Securities Clearing Company Limited	44,044,499	Domestic shares denominated in RMB	44,044,499
China AMC – Agricultural Bank – Huaxia China Securities Financial Asset Management Plan	8,795,136	Domestic shares denominated in RMB	8,795,136
Zhongou AMC – Agricultural Bank – Zhongou China Securities Financial Asset Management Plan	8,680,636	Domestic shares denominated in RMB	8,680,636
Boshi AMC – Agricultural Bank – Boshi China Securities Financial Asset Management Plan	8,662,836	Domestic shares denominated in RMB	8,662,836
Dacheng AMC – Agricultural Bank – Dacheng China Securities Financial Asset Management Plan	8,657,836	Domestic shares denominated in RMB	8,657,836
Explanation on the connection or parties acting in concert among the above shareholders	(1)	According to the information provided by HKSCC Nominees Limited, the H shares held by it were held on behalf of clients.	
	(2)	The Company was not aware of any connection among the above top ten shareholders, or whether they were parties acting in concert as provided in the “Measures Governing the Acquisition by Listed Companies”.	
Explanation on the participation in margin trading and refinancing business of the top ten shareholders and the top ten shareholders not subject to selling restrictions of the Company (if any)	Not applicable		

3. OTHER MATTERS

Other important information about the operation of the Company during the Reporting Period that investors should be reminded of

Applicable Not applicable

4. QUARTERLY FINANCIAL STATEMENTS

4.1 Type of audit opinion

Applicable Not applicable

4.2 Financial Statements

Consolidated Balance Sheet

As at 30 September 2022

Items	30 September 2022 (RMB)	31 December 2021 (RMB)
Current assets:		
Cash at bank and on hand	21,672,994,078.24	22,376,927,861.43
Settlement provisions	–	–
Funds lent	–	–
Financial assets held for trading	50,668,596.07	–
Derivative financial assets	–	–
Notes receivable	1,185,670,256.51	1,222,097,099.65
Accounts receivable	15,161,540,224.09	12,816,537,107.40
Accounts receivable financing	2,613,007,583.48	3,171,865,961.20
Advances to suppliers	620,050,975.07	779,239,826.44
Premiums receivable	–	–
Cession insurance premiums receivable	–	–
Provision for insurance contracts	–	–
Other receivables	1,045,166,482.93	1,178,714,393.77
Including: Interest receivable	–	–
Dividend receivable	218,766,959.00	343,766,959.00
Financial assets purchased under resale agreements	–	–
Inventories	8,439,785,396.38	10,437,733,799.99
Contract assets	–	–
Classified as assets held for sale	–	–
Current portion of non-current assets	647,527,363.37	–
Other current assets	1,422,023,087.48	827,458,411.57
Total current assets	52,858,434,043.62	52,810,574,461.45

Items	30 September 2022 <i>(RMB)</i>	31 December 2021 <i>(RMB)</i>
Non-currents assets:		
Entrusted loans and advances	–	–
Debt investment	2,933,643,248.27	630,712,084.75
Other debt investment	–	–
Long-term receivables	–	–
Long-term equity investment	1,652,999,740.16	1,562,878,567.36
Other equity instrument investment	116,376,377.50	123,422,079.79
Other non-current financial assets	1,170,680,053.17	574,277,570.93
Investments properties	208,448,956.50	213,975,748.27
Fixed assets	3,597,668,477.89	3,347,591,974.10
Construction in progress	1,752,473,268.73	1,564,091,121.32
Bearer biological assets	2,542,417.50	2,804,475.00
Oil and gas assets	–	–
Right-of-use assets	693,017,954.82	769,839,539.91
Intangible assets	2,548,516,059.38	2,582,390,492.30
Development expenditure	13,836,804.70	10,567,467.71
Goodwill	829,473,066.90	829,473,066.90
Long-term prepaid expenses	140,999,877.18	132,477,737.46
Deferred tax assets	813,125,124.65	794,232,420.03
Other non-current assets	220,372,863.35	168,480,956.67
	<hr/>	<hr/>
Total non-current assets	16,694,174,290.70	13,307,215,302.50
	<hr/>	<hr/>
Total Assets	69,552,608,334.32	66,117,789,763.95
	<hr/>	<hr/>

Items	30 September 2022 (RMB)	31 December 2021 (RMB)
Current liabilities:		
Short-term borrowings	8,430,524,750.45	8,428,008,311.52
Borrowings from central banks	-	-
Deposits funds	-	-
Financial liabilities held for trading	-	-
Derivative financial liabilities	-	-
Notes payable	3,436,696,924.00	3,445,815,661.30
Accounts payable	11,718,192,211.12	11,287,152,869.54
Advances from customers	-	-
Contract liabilities	1,150,560,577.93	2,740,338,069.29
Financial assets sold under repurchase agreements	-	-
Deposits from customers and interbank	-	-
Funds received as agent of stock exchange	-	-
Funds received as stock underwrite	-	-
Employee benefits payable	976,886,307.75	949,975,749.08
Taxes payable	478,371,799.29	233,496,725.47
Other payables	4,422,327,292.58	4,577,200,581.59
Including: Interest payable	-	460,278.35
Dividends payable	54,409,595.68	55,789,451.94
Handling charges and commissions payable	-	-
Cession insurance premiums payable	-	-
Liabilities held for sales	-	-
Current portion of non-current liabilities	636,403,426.95	245,802,906.86
Other current liabilities	737,058,192.69	346,060,329.07
Total current liabilities	<u>31,987,021,482.76</u>	<u>32,253,851,203.72</u>
Non-current liabilities:		
Insurance contract reserve	-	-
Long-term borrowings	1,751,899,917.15	752,812,083.34
Bonds payable	-	-
Including: Preferred stock	-	-
Perpetual bond	-	-
Lease liabilities	476,447,098.46	497,697,835.96
Long-term payables	20,396,504.60	20,464,502.00
Long-term employee benefits payable	322,200.06	304,247.44
Provisions	44,543,767.09	53,974,538.25
Deferred income	986,568,392.78	826,859,462.22
Deferred tax liabilities	353,264,796.47	331,727,982.44
Other non-current liabilities	53,147,770.30	53,429,349.59
Total non-current liabilities	<u>3,686,590,446.91</u>	<u>2,537,270,001.24</u>
Total Liabilities	<u>35,673,611,929.67</u>	<u>34,791,121,204.96</u>

Items	30 September 2022 (RMB)	31 December 2021 (RMB)
Shareholders' equity:		
Share capital	1,625,790,949.00	1,625,790,949.00
Other equity instruments	-	-
Including: Preferred stock	-	-
Perpetual bond	-	-
Capital surplus	9,957,004,727.02	9,956,953,383.38
Less: Treasury shares	-	-
Other comprehensive income	(8,343,489.89)	(17,476,356.88)
Special reserve	-	-
Surplus reserve	1,908,713,749.53	1,908,713,749.53
General risk provision	-	-
Undistributed profits	<u>17,945,651,185.68</u>	<u>15,588,202,733.48</u>
Total equity attributable to the Shareholders of the parent Company	31,428,817,121.34	29,062,184,458.51
Minority interest	<u>2,450,179,283.31</u>	<u>2,264,484,100.48</u>
Total Shareholders' Equity	<u>33,878,996,404.65</u>	<u>31,326,668,558.99</u>
Total Liabilities and Shareholders' Equity	<u>69,552,608,334.32</u>	<u>66,117,789,763.95</u>

*Person in charge of
the Company*

Mr. Li Chuyuan

*Principal in charge of
accounting*

Ms. Liu Fei

*Head of accounting
department*

Ms. Wu Chuling

Consolidated Income Statement
1 January – 30 September 2022

Items	1 January - 30 September 2022 (RMB)	1 January - 30 September 2021 (RMB)
1. Total operating income	54,805,915,266.27	53,539,542,415.85
Including: Operating income	54,805,915,266.27	53,539,542,415.85
Interest Income	-	-
Premiums earned	-	-
Fees and commissions income	-	-
2. Total operating costs	50,741,822,510.39	49,470,087,334.14
Including: Operating cost	43,968,089,080.34	42,705,386,796.49
Interest expense	-	-
Fees and commissions expense	-	-
Surrenders	-	-
Net claims paid	-	-
Net reserves for insurance contracts	-	-
Policyholder dividends	-	-
Reinsurance expenses	-	-
Taxes and surcharges	226,774,195.72	237,021,334.18
Selling and distribution expenses	4,461,479,964.77	4,572,348,972.25
General and administrative expenses	1,584,036,471.41	1,468,651,734.02
R&D expenses	664,386,145.53	604,708,177.54
Financial expenses	(162,943,347.38)	(118,029,680.34)
Including: Interest expense	310,292,381.67	309,209,999.86
Interest income	494,625,816.62	444,557,092.80
Add: Other income	358,465,058.48	98,974,290.56
Investment income (“-” for loss)	102,078,630.07	157,621,054.72
Including: Income from investments in associates and joint ventures	82,572,686.00	154,149,537.43
Gains on termination of financial assets measured at amortized cost (“-” for loss)	(5,368,439.21)	-
Exchange gains and losses (“-” for loss)	-	-
Gains on hedging of net exposure (“-” for loss)	-	-
Gains from changes in fair value (“-” for loss)	(5,452,102.92)	(9,669,024.36)
Impairment losses in respect of credit (“-” for loss)	(46,061,989.98)	(40,981,028.72)
Impairment losses in respect of assets (“-” for loss)	(12,712,941.94)	(14,845,484.93)
Gains from disposal of assets (“-” for loss)	881,980.94	1,858,123.81

Items	1 January - 30 September 2022 (RMB)	1 January - 30 September 2021 (RMB)
3. Operating profit (“-” for loss)	<u>4,461,291,390.53</u>	<u>4,262,413,012.79</u>
Add: Non-operating income	13,494,473.69	17,033,752.53
Less: Non-operating expenses	17,833,038.11	74,402,743.21
4. Total profit (“-” for loss)	<u>4,456,952,826.11</u>	<u>4,205,044,022.11</u>
Less: Income tax expenses	772,220,229.87	695,868,664.28
5. Net profit (“-” for loss)	<u>3,684,732,596.24</u>	<u>3,509,175,357.83</u>
(1) Classified by the continuity of operations		
A. Net profit from continuing operations (“-” for loss)	3,684,732,596.24	3,509,175,357.83
B. Net profit from discontinued operations (“-” for loss)	-	-
(2) Classified by ownership of the equity		
A. Net profit attributable to the parent company’s shareholders (“-” for loss)	3,474,366,834.16	3,311,742,664.03
B. Minority interest (“-” for loss)	210,365,762.08	197,432,693.80
6. Other comprehensive income, net of tax	9,361,952.70	(717,220.13)
Other comprehensive income, net of tax attributable to the parent company’s shareholders	9,132,866.99	(1,513,983.25)
(1) Other comprehensive income that will not be reclassified to profit or loss	(9,274,046.44)	(1,131,572.23)
A. Changes arising from the remeasurement of defined benefit obligation	-	-
B. Other comprehensive income that will not be reclassified to profit or loss under equity method	-	-
C. Changes in fair value of other equity instrument investments	(9,274,046.44)	(1,131,572.23)
D. Change in fair value of the company’s own credit risk	-	-

Items	1 January - 30 September 2022 (RMB)	1 January - 30 September 2021 (RMB)
(2) Other comprehensive income that may be reclassified into profit or loss	18,406,913.43	(382,411.02)
A. Other comprehensive income that may be reclassified to profit or loss under equity method	-	-
B. Change in fair value of other debt investments	(333,946.60)	(2,238,105.27)
C. Gains and losses arising from changes in fair value of available-for-sale financial assets	-	-
D. Provision for credit loss of other debt investments	945,203.19	4,364,063.69
E. Cash flow hedge reserve	-	-
F. Difference arising from the translation of foreign currency financial statements	17,795,656.84	(2,508,369.44)
G. Others	-	-
Other comprehensive income, net of tax attributable to minority shareholders	229,085.71	796,763.12
7. Total comprehensive income	<u>3,694,094,548.94</u>	<u>3,508,458,137.70</u>
Total comprehensive income attributable to shareholders of the parent company	3,483,499,701.15	3,310,228,680.78
Total comprehensive income attributable to minority shareholders	210,594,847.79	198,229,456.92
8. Earnings per share		
(1) Basic earnings per share (RMB/Share)	2.137	2.037
(2) Diluted earnings per share (RMB/Share)	2.137	2.037

If business combination happened under the same control during the Reporting Period, the combined party recognized the net profit of RMB0 and 0 before combination and the corresponding period last year, collectively.

<i>Person in charge of the Company</i>	<i>Principal in charge of accounting</i>	<i>Head of accounting department</i>
Mr. Li Chuyuan	Ms. Liu Fei	Ms. Wu Chuling

Consolidated Cash Flow Statement

1 January – 30 September 2022

Items	1 January – 30 September 2022 (RMB)	1 January – 30 September 2021 (RMB)
1. Cash flows from operating activities		
Cash received from sale of goods and rendering of services	51,211,003,607.23	51,793,363,131.13
Customer deposits and interbank net increase in deposits	–	–
Net increase in borrowings from central banks	–	–
Borrowing funds from other financial institutions net increase	–	–
Receipt of the original insurance contract cash	–	–
Net cash received from reinsurance business	–	–
Net increase in policyholders' deposits and investments	–	–
Charge interest, fees and commissions	–	–
Net increase in placements from banks and the financial institutions	–	–
Net increase in repo operations funds	–	–
Net cash received from customer brokerage deposits	–	–
Refund of taxes and surcharges	61,993,639.65	18,440,546.51
Cash received relating to other operating activities	1,315,124,509.88	1,360,832,935.50
Sub-total of cash inflows	<u>52,588,121,756.76</u>	<u>53,172,636,613.14</u>
Cash paid for goods and services	40,388,724,813.85	38,960,003,881.98
Net increase in loans and advances to customers	–	–
Central banks and interbank deposits cash	–	–
Pay the original insurance contract paid in cash	–	–
Net increase in loans to banks and other financial institutions	–	–
Payment of interest, fees and commissions	–	–
Commissions on insurance policies paid	–	–
Cash paid to and on behalf of employees	4,185,455,900.21	3,891,407,699.58
Payments of taxes and surcharges	2,214,578,250.74	2,286,607,930.36
Cash paid relating to other operating activities	2,499,892,793.89	2,249,133,619.70
Sub-total of cash outflows	<u>49,288,651,758.69</u>	<u>47,387,153,131.62</u>
Net cash flows from operating activities	<u><u>3,299,469,998.07</u></u>	<u><u>5,785,483,481.52</u></u>

Items	1 January – 30 September 2022 (RMB)	1 January – 30 September 2021 (RMB)
2. Cash flows from investing activities		
Cash received from disposal of investments	102,700,000.00	279,000,000.00
Cash received from returns on investments	149,271,575.88	126,139,202.67
Net cash received from disposal of fixed assets, intangible assets and other long-term assets	1,223,028.04	6,447,450.36
Net cash received from sales of subsidiaries and other business units	–	33,386,871.10
Cash received from other investing activities	21,539.12	148,630.88
Sub-total of cash inflows	<u>253,216,143.04</u>	<u>445,122,155.01</u>
Cash paid to acquire fixed assets, intangible assets and other long-term assets	898,323,881.67	770,279,864.17
Cash paid to acquire investments	5,226,825,588.75	235,162,500.00
Net increase in loans	–	–
Net cash paid for acquire subsidiaries and other business units	1,900,000.00	–
Cash paid relating to other investing activities	–	–
Sub-total of cash outflows	<u>6,127,049,470.42</u>	<u>1,005,442,364.17</u>
Net cash flows from investing activities	<u>(5,873,833,327.38)</u>	<u>(560,320,209.16)</u>
3. Cash flows from financing activities		
Cash received from capital contributions	1,180,000.00	3,090,000.00
Including: Cash received from capital contributions by minority shareholders to subsidiaries	1,180,000.00	3,090,000.00
Cash received from borrowings	8,441,218,967.30	7,819,274,235.86
Cash received relating to other financing activities	2,941,691,884.02	2,202,894,832.01
Sub-total of cash inflows	<u>11,384,090,851.32</u>	<u>10,025,259,067.87</u>
Cash payments of borrowings	6,139,007,297.68	6,791,322,409.96
Cash payments for interest expenses and distribution of dividends or profits	1,424,071,946.01	1,192,629,895.40
Including: Cash payments for dividends or profit to minority shareholders of subsidiaries	25,184,786.31	30,717,171.86
Cash payments relating to other financing activities	2,529,737,659.34	2,261,686,909.72
Sub-total of cash outflows	<u>10,092,816,903.03</u>	<u>10,245,639,215.08</u>

Items	1 January – 30 September 2022 (RMB)	1 January – 30 September 2021 (RMB)
Net cash flows from financing activities	<u>1,291,273,948.29</u>	<u>(220,380,147.21)</u>
4. Effects of foreign exchange rate changes on cash and cash equivalents	<u>(876,304.70)</u>	<u>255,827.94</u>
5. Net increase in cash and cash equivalents	(1,283,965,685.72)	5,005,038,953.09
Add: Cash and cash equivalents at the beginning of the period	<u>21,013,364,042.22</u>	<u>17,765,132,774.10</u>
6. Cash and cash equivalents at the end of the period	<u>19,729,398,356.50</u>	<u>22,770,171,727.19</u>

*Person in charge of
the Company*
Mr. Li Chuyuan

*Principal in charge of
accounting*
Ms. Liu Fei

*Head of accounting
department*
Ms. Wu Chuling

The adjustments to financial statements at the beginning of the year related to implementation of new accounting standards or interpretation of standards for the first time since 2022.

Applicable Not applicable

The Board of
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited

Guangzhou, the PRC, 25 October 2022

As at the date of this report, the Board comprises Mr. Li Chuyuan, Mr. Yang Jun, Ms. Cheng Ning, Ms. Liu Juyan, Mr. Zhang Chunbo, Mr. Wu Changhai and Mr. Li Hong as executive directors, and Mr. Wong Hin Wing, Ms. Wang Weihong, Mr. Chen Yajin, and Mr. Huang Min as independent non-executive directors.